-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EIsGOqantMrgYLZI8iRToN/mJNYklEcwnSJM5CZ1NuLkrgt/gEamCHpcP7NKT5xc djCTdyNvglaeBq07KsbXdA== 0001144204-09-008931.txt : 20090217 0001144204-09-008931.hdr.sgml : 20090216 20090217155937 ACCESSION NUMBER: 0001144204-09-008931 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081231 FILED AS OF DATE: 20090217 DATE AS OF CHANGE: 20090217 EFFECTIVENESS DATE: 20090217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 09613519 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v139940_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: December 31, 2008 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 21st Floor -------------------------------------------- New York, NY 10065-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. February 12, 2009 - -------------------------- --------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 95 ----------- Form 13F Information Table Entry Value: 1,079,209 ----------- (thousands) List of Other Included Managers: None Baker Brothers Form 13F 12-31-2008
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY Name of Issuer CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ---------------------------- ------- ------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 1,785 1,983,474 SH SOLE 1,983,474 Acorda Therapeutics COM 00484M106 29,388 1,432,860 SH SOLE 1,432,860 Adolor Corp. COM 00724X102 389 234,515 SH SOLE 234,515 Allergan COM 018490102 1,456 36,100 SH SOLE 36,100 Allos Therapeutics Inc. COM 019777101 68,842 11,248,621 SH SOLE 11,248,621 Alsius Corp. COM 021211107 29 64,850 SH SOLE 64,850 Altus Pharmaceuticals Inc. COM 02216N105 38 71,477 SH SOLE 71,477 Amgen COM 031162100 5,486 95,000 SH SOLE 95,000 Amicus Therapeutics COM 03152W109 10,720 1,343,298 SH SOLE 1,343,298 Anadys Pharmaceuticals Inc. COM 03252Q408 702 447,835 SH SOLE 447,835 AP Pharma COM 00202J203 1,212 2,884,546 SH SOLE 2,884,546 Aradigm Corp. COM 038505301 25 100,000 SH SOLE 100,000 Ardea Biosciences Inc. COM 03969P107 61,940 5,174,655 SH SOLE 5,174,655 Autoimmune Inc. COM 052776101 28 26,100 SH SOLE 26,100 Auxilium COM 05334D107 117,258 4,122,997 SH SOLE 4,122,997 Biocryst Pharmaceuticals Inc. COM 09058V103 8,741 6,380,689 SH SOLE 6,380,689 Cadence Pharmaceuticals COM 12738T100 1,126 155,784 SH SOLE 155,784 Celgene COM 151020104 33,611 608,019 SH SOLE 608,019 Cepheid COM 15670R107 624 60,100 SH SOLE 60,100 Chelsea Therapeutics COM 163428105 1,523 1,136,263 SH SOLE 1,136,263 Critical Therapeutics Inc. COM 22674T105 298 112,443 SH SOLE 112,443 Cubist COM 229678AC1 4,136 171,193 SH SOLE 171,193 Curagen COM 23126R101 179 388,613 SH SOLE 388,613 Cyclacel Pharmaceuticals COM 23254L108 78 186,086 SH SOLE 186,086 Cyclacel Pharmaceuticals Pfd. Conv. Ex 6% PFD CONV EX 23254L207 144 95,500 SH SOLE 95,500 Cytokinetics Inc. COM 23282W100 4,039 1,417,212 SH SOLE 1,417,212 Depomed COM 249908104 302 183,145 SH SOLE 183,145 Genelabs Technologies Inc. COM 368706206 200 154,937 SH SOLE 154,937 Genentech COM 368710406 1,575 19,000 SH SOLE 19,000 Genomic Health Inc. COM 37244C101 101,303 5,200,387 SH SOLE 5,200,387 Halozyme Therapeutics Inc. COM 40637H109 11,361 2,028,709 SH SOLE 2,028,709 Icagen Inc. COM 45104P104 25 46,373 SH SOLE 46,373 Idera Pharmaceuticals Inc. COM 45168K108 4,000 520,897 SH SOLE 520,897 Immunogen Inc. COM 45253H101 2,159 503,334 SH SOLE 503,334 Immunomedics, Inc. COM 452907108 81 47,704 SH SOLE 47,704 Incyte Corp. COM 45337C102 42,092 11,106,114 SH SOLE 11,106,114 Indevus Pharmaceuticals COM 454072109 5,108 1,626,910 SH SOLE 1,626,910 Infinity Pharmaceuticals Inc. COM 45665G303 684 85,632 SH SOLE 85,632 Inhibitex Inc. COM 45719T103 162 620,904 SH SOLE 620,904 Inspire COM 457733103 12,459 3,460,912 SH SOLE 3,460,912 Intermune Inc. COM 45884X103 4,632 437,801 SH SOLE 437,801 Inverness Medical COM 46126P106 9,417 497,980 SH SOLE 497,980 Medarex COM 583916101 1,642 294,289 SH SOLE 294,289 Metabasis Therapeutics Inc. COM 59101M105 733 2,290,668 SH SOLE 2,290,668 Micromet COM 59509C105 16,239 3,724,585 SH SOLE 3,724,585 Myriad Genetics Inc. COM 62855J104 17,683 266,875 SH SOLE 266,875 Neose Technologies Inc. COM 640522108 765 2,251,191 SH SOLE 2,251,191 Neurocrine Biosciences COM 64125C109 134 41,861 SH SOLE 41,861 Neurogen Corp. COM 64124E106 1,181 8,205,406 SH SOLE 8,205,406 Novo-Nordisk COM 670100205 15,020 295,646 SH SOLE 295,646 Onyx Inc. COM 683399109 1,250 36,578 SH SOLE 36,578 Optimer Pharmaceuticals COM 68401H104 5,137 424,251 SH SOLE 424,251 OSI Pharmaceuticals COM 671040103 1,763 45,144 SH SOLE 45,144 Pharmasset Inc. COM 71715N106 868 66,247 SH SOLE 66,247 Salix Pharmaceuticals, Inc. COM 795435106 41,591 4,710,207 SH SOLE 4,710,207 Seattle Genetics Inc. COM 812578102 115,434 12,912,124 SH SOLE 12,912,124 Sequenom Inc. COM 817337405 231 11,645 SH SOLE 11,645 Siga Technologies Inc. COM 826917106 1,243 380,202 SH SOLE 380,202 Spectrum Pharmaceuticals Inc. COM 84763A108 265 177,779 SH SOLE 177,779 Sucampo CLASS A 864909106 370 64,387 SH SOLE 64,387 Sunesis Pharmaceuticals Inc. COM 867328502 412 1,286,466 SH SOLE 1,286,466 Supergen COM 868059106 633 331,480 SH SOLE 331,480 Symyx Technologies, Inc. COM 87155S108 434 73,127 SH SOLE 73,127 Targacept COM 87611R306 1,513 425,073 SH SOLE 425,073 Threshold Pharma COM 885807107 858 1,504,711 SH SOLE 1,504,711 Torreypines Therapeutics COM 89235K105 9 33,546 SH SOLE 33,546 Trimeris Inc. COM 896263100 4,638 3,461,175 SH SOLE 3,461,175 Vanda Pharmaceuticals Inc. COM 921659108 113 225,142 SH SOLE 225,142 Via Pharmaceuticals COM 92554T103 19 102,881 SH SOLE 102,881 Vion Pharm COM 927624AA4 16 43,101 SH SOLE 43,101 Viropharma Inc. COM 928241108 87,559 6,724,903 SH SOLE 6,724,903 Xenoport Inc. COM 98411C100 14,349 572,133 SH SOLE 572,133 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 16,836 23,465,000 PRN SOLE 23,465,000 Biomarin Pharmaceuticals Notes 1.875% 4/23/2017 CONV BONDS 09061GAD3 29,800 32,000,000 PRN SOLE 32,000,000 Biomarin Pharmaceuticals Notes 2.5% 3/29/2013 CONV BONDS 09061GAC5 20,593 18,224,000 PRN SOLE 18,224,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 13,329 25,089,000 PRN SOLE 25,089,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAF9 17,581 33,250,000 PRN SOLE 33,250,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 20,481 24,713,000 PRN SOLE 24,713,000 Medarex Inc Notes 2.25% 5/15/2011 CONV BONDS 583916AG6 9,165 13,158,000 PRN SOLE 13,158,000 Vertex Pharmaceuticals Notes 4.75% 2/15/13 CONV BONDS 92532FAM2 35,484 25,948,000 PRN SOLE 25,948,000 Viropharma Inc. Notes 2.0% 3/15/2017 CONV BONDS 928241AH1 34,481 45,000,000 PRN SOLE 45,000,000 1,079,209 =====================
-----END PRIVACY-ENHANCED MESSAGE-----